IRulya Therapeutics (IRLA) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about IRLA filings

Are insiders buying or selling IRulya Therapeutics Inc. (IRLA) stock?

Neither. IRulya Therapeutics Inc. (IRLA) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IRLA recently?

None. No member of Congress disclosed a IRLA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IRLA smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

Questions about IRLA filings

Are insiders buying or selling IRulya Therapeutics Inc. (IRLA) stock?

Neither. IRulya Therapeutics Inc. (IRLA) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IRLA recently?

None. No member of Congress disclosed a IRLA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IRLA smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 11, 2026

Earnings came in $50.83 a share above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 11, 2026

Period ending

Sep 30, 2026

Earnings per share

$50.00+$50.83 beat

-$0.83 expected

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing · No operating revenue

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$1.11

-$1.60 to -$0.71

Estimate drift

0.25

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 11, 2026	$50.00est. -$0.83	+$50.83beat	Not on file	Not on file
Jun 30, 2026Reported Aug 14, 2026	-$12.15est. -$12.39	+1.88%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 11, 2026	$57.60est. -$52.00	+$109.60beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Apr 10, 2026	-$152.00est. -$45.00	-$107.00miss	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 12, 2025	-$50.00est. -$44.50	-12.36%miss	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2025Reported Aug 12, 2025	-$68.75Reported	No estimate	Not on file	Not on file
Mar 31, 2025Reported May 13, 2025	-$68.41Reported	No estimate	Not on file	Not on file
Dec 31, 2024Reported Mar 25, 2025	-$56.78Reported	No estimate	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

52-wk high: $910.00
52-wk low: $15.10
Mkt cap: $415.6M
ROE: -153.8%
Beta: 1.79
P/B: 2.2x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $416M

Valuation

P/B2.21

Quality

Operating margin0.0%
ROE-153.8%
ROA-31.5%

Growth

Beta1.79

Technicals

Price structure

Market data unavailable.

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about IRLA filings

Are insiders buying or selling IRulya Therapeutics Inc. (IRLA) stock?

Neither. IRulya Therapeutics Inc. (IRLA) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IRLA recently?

None. No member of Congress disclosed a IRLA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IRLA smart-money data?

No recent filings found.

Questions about IRLA filings

Are insiders buying or selling IRulya Therapeutics Inc. (IRLA) stock?

Neither. IRulya Therapeutics Inc. (IRLA) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IRLA recently?

None. No member of Congress disclosed a IRLA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IRLA smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 11, 2026

Earnings came in $50.83 a share above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 11, 2026

Period ending

Sep 30, 2026

Earnings per share

$50.00+$50.83 beat

-$0.83 expected

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing · No operating revenue

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$1.11

-$1.60 to -$0.71

Estimate drift

0.25

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 11, 2026	$50.00est. -$0.83	+$50.83beat	Not on file	Not on file
Jun 30, 2026Reported Aug 14, 2026	-$12.15est. -$12.39	+1.88%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 11, 2026	$57.60est. -$52.00	+$109.60beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Apr 10, 2026	-$152.00est. -$45.00	-$107.00miss	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 12, 2025	-$50.00est. -$44.50	-12.36%miss	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2025Reported Aug 12, 2025	-$68.75Reported	No estimate	Not on file	Not on file
Mar 31, 2025Reported May 13, 2025	-$68.41Reported	No estimate	Not on file	Not on file
Dec 31, 2024Reported Mar 25, 2025	-$56.78Reported	No estimate	Not on file	Not on file

52-wk high: $910.00
52-wk low: $15.10
Mkt cap: $415.6M
ROE: -153.8%
Beta: 1.79
P/B: 2.2x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $416M

Valuation

P/B2.21

Quality

Operating margin0.0%
ROE-153.8%
ROA-31.5%

Growth

Beta1.79

Technicals

Price structure

Market data unavailable.

IRulya Therapeutics Inc.

Smart money at a glance

What do analysts expect?

Questions about IRLA filings

Questions about IRLA filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in $50.83 a share above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

IRulya Therapeutics Inc.

Smart money at a glance

What do analysts expect?

Questions about IRLA filings

Questions about IRLA filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in $50.83 a share above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

IRulya Therapeutics Inc.

Overview

Questions about IRLA filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

IRulya Therapeutics Inc.

Overview

Questions about IRLA filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.